Sahil Khanna, MBBS: Emerging Therapies for C Difficile

October 20, 2021
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

Recent studies have shown the majority of potential FMT donors are ultimately rejected.

Much of the focus in recent years in new therapies for Clostridioides difficile infections (CDI) has centered on fecal microbiota transplantation (FMT).

Fecal microbiota transplantation is a procedure where healthy donor stool is infused to rectify the recipient’s intestinal microbial community by introducing micro-organisms associated with a health state to normalize microbiota composition and function.

This treatment has shown promise, particularly in treating recurrent CDI. However, it can be a struggle finding suitable donors.

Donors are often rejected for a number of reasons, ranging from high body mass index (BMI) to underlying chronic illnesses to recent use of antibiotics.

While it is challenging to find suitable donors, a small sampling of donors can make a big difference.

In an interview with HCPLive®, Sahil Khanna, MBBS, Professor of Medicine, Mayo Clinic, explained why FMT has so much promise and why it is not too concerning that only a small percentage of donor candidates materialize.

Khanna said unlike blood donors who have a limit to how much blood they can donate, a small amount of stool donors are able to produce a large amount of donations.

On October 14, Khanna chaired an HCPLive State of Science event called Institutional Perspectives in Infectious Diseases: Management of C. Difficile.


x